Impact of clinical and non-clinical factors on the choice of HER2 test for breast cancer

Cancer Investigation

Volumn 28, Issue 7, 2010, Pages 735-742

  Ashok, Mahima ^a   Griffin, Paul ^b   Halpern, Michael ^c  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

Breast Cancers; Detection Diagnosis; Guidelines

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; FLUORESCENCE IN SITU HYBRIDIZATION; GEOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION;

AGE FACTORS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CHOICE BEHAVIOR; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INSURANCE CARRIERS; MODELS, BIOLOGICAL; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 77954789178     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.496753     Document Type: Article

References (48)

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta, GA: American Cancer Society, 2008.
2. Ferretti, G.; Felici, A.; Papaldo, P.; Fabi, A.; Cognetti, F. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 2007, 19, 56-62.
3. Wang, S.; Saboorian, M.H.; Frenkel, E.; Hynan, L.; Gokaslan, S.T.; Ashfaq, R. Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000, 53, 374-381.
4. Yaziji, H.; Goldstein, L.C.; Barry, T.S.;Werling, R.; Hwang, H.; Ellis, G.K.; Gralow, J.R.; Livingston, R.B.; Gown, A.M. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004, 291, 1972-1977. (Pubitemid 38544278)
5. Dybdal, N.; Leiberman, G.; Anderson, S.;McCune, B.; Bajamonde, A.; Cohen, R.L.; Mass, R.D.; Sanders, C.; Press, M.F. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005, 93, 3-11.
6. Hoang, M.P.; Sahin, A.A.; Ordonez, N.G.; Sneige, N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000, 113, 852-859.
7. Vincent-Salomon, A.; MacGrogan, G.; Couturier, J.; Arnould, L.; Denoux, Y.; Fiche, M.; Jacquemier, J.; Mathieu, M.C.; Penault- Llorca, F.; Rigaud, C.; Roger, P.; Treilleux, I.; Vilain, M.O.; Mathoulin-Ṕ elissier, S.; Le Doussal, V. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 2003, 42, 337-347.
8. Tsuda, H. HER-2 (c-erbB-2) test update: present status and problems. Breast Cancer 2006, 13, 236-248.
9. Sauer, T.; Wiedswang, G.; Boudjema, G.; Christensen, H.; Karesen, R. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice? APMIS 2003, 111, 444-450.
10. Levsky, J.M.; Singer, R.H. Fluorescence in situ hybridization: past, present and future. J Cell Sci 2003, 116, 2833-2838.
11. Bartlett, J.M.; Going, J.J.; Mallon, E.A.; Watters, A.D.; Reeves, J.R.; Stanton, P.; Richmond, J.; Donald, B.; Ferrier, R.; Cooke, T.G. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001, 195, 422-428. (Pubitemid 33069666)
12. Tubbs, R.R.; Pettay, J.D.; Roche, P.C.; Stoler, M.H.; Jenkins, R.B.; Grogan, T.M. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001, 19, 2714-2721.
13. Ridolfi, R.L.; Jamehdor, M.R.; Arber, J.M. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000, 13, 866-873.
14. Bilous, M.; Dowsett, M.; Hanna, W.; Isola, J.; Lebeau, A.; Moreno, A.; Penault-Llorca, F.; Rüschoff, J.; Tomasic, G.; van de Vijver, M. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003, 16, 173-182.
15. Kakar, S.; Puangsuvan, N.; Stevens, J.M.; Serenas, R.; Mangan, G.; Sahai, S.; Mihalov, M.L. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 2000, 5, 199-207.
16. Lebeau, A.; Deimling, D.; Kaltz, C.; Sendelhofert, A.; Iff, A.; Luthardt, B.; Untch, M.; Löhrs, U. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001, 19, 354-363.
17. McCormick, S.R.; Lillemoe, T.J.; Beneke, J.; Schrauth, J.; Reinartz, J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 2002, 117, 935-943.
18. Lal, P.; Salazar, P.A.; Hudis, C.A.; Ladanyi, M.; Chen, B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004, 121, 631-636.
19. Jimenez, R.E.; Wallis, T.; Tabasczka, P.; Visscher, D. W. Determination of HER-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000, 13, 37-45.
20. Tsuda, H.; Akiyama, F.; Terasaki, H.; Hasegawa, T.; Kurosumi, M.; Shimadzu, M.; Yamamori, S.; Sakamoto, G. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 2001, 92, 2965-2974.
21. Jacobs, T.W.; Gown, A.M.; Yaziji, H.; Barnes, M.J.; Schnitt, S.J. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999, 17, 1974-1982.
22. Elkin, E.B.;Weinstein, M.C.; Winer, E.P.; Kuntz, K.M.; Schnitt, S.J.; Weeks, J.C. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004, 22, 854-863.
23. Wolff, A.C.; Hammond, M.E.; Schwartz, J.N.; Hagerty, K.L.; Allred, D.C.; Cote, R.J.; Dowsett, M.; Fitzgibbons, P.L.; Hanna, W.M.; Langer, A.; McShane, L.M.; Paik, S.; Pegram, M.D.; Perez, E.A.; Press, M.F.; Rhodes, A.; Sturgeon, C.; Taube, S.E.; Tubbs, R.; Vance, G.H.; van de Vijver, M.; Wheeler, T.M.; Hayes, D.F. American Society of Clinical Oncology/College of American Pathologists guidelines recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25, 118-145. (Pubitemid 350003059)
24. Mass, R.; Sanders, C.; Kasian, C.; Johnson, L.; Everett, T.; Anderson, S. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Soc Clin Oncol 2000, 19, 75a (abstr 291).
25. Mass, R.D.; Press, M.; Anderson, S.; Murphy, M.; Slamon, D. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization. Proc Am Soc Oncol 2001, 20, 22a (abstr 85).
26. Press, M.F.; Slamon, D.; Cobleigh, M. Improved clinical outcomes for Herceptin-treated patients selected by fluorescence in situ hybridization. Lab Invest 2002, 82, 47A.
27. Vogel, C.L.; Cobleigh, M.A.; Tripathy, D.; Gutheil, J.C.; Harris, L.N.; Fehrenbacher, L.; Slamon, D.J.; Murphy, M.; Novotny, W.F.; Burchmore, M.; Shak, S.; Stewart, S.J.; Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20, 719-726.
28. Newman, L.A.; Kuerer, H.M.; Hunt, K.K.; Singh, G.; Ames, F.C.; Feig, B.W.; Ross, M.I.; Taylor, S.; Singletary, S.E. Local recurrence and survival among black women with early-stage breast cancer treated with breast-conservation therapy or mastectomy. Ann Surg Oncol 1999, 6, 241-248.
29. Muss, H.B.; Hunter, C.P.; Wesley, M.; Correa, P.; Chen, V.W.; Greenberg, R.S.; Eley, J.W.; Austin, D.F.; Kurman, R.; Edwards, B.K. Treatment plans for black and white women with stage II node-positive breast cancer. The National Cancer Institute Black/White Cancer Survival Study experience. Cancer 1992, 70, 2460-2467.
30. Dignam, J.J.; Colangelo, L.; Tian, W.; Jones, J.; Smith, R.; Wickerham, D.L.; Wolmark, N. Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst 1999, 91, 1933-1940.
31. Katz, S.J.; Zemencuk, J.K.; Hofer, T.P. Breast cancer screening in the United States and Canada: socioeconomic gradients persist. Am J Public Health 2000, 90, 799-803.
32. Ghafoor, A.; Jemal, A.; Ward, E.; Cokkinides, V.; Smith, R.; Thun, M. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2003, 53, 342.
33. Chu, K.C.; Lamar, C.A.; Freeman, H.P. Racial disparities in breast carcinoma survival rates. Cancer 2003, 97(11), 2853-2860.
34. Ayanian, J.Z.; Kohler, B.A.; Abe, T.; Epstein, A.M. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med 1993, 329, 5, 326-331.
35. National Cancer Institute. Surveillance epidemiology and end results. Retrieved March 4, 2009, from http://seer.cancer.gov/.
36. Commission on Cancer and the American Cancer Society. National Cancer Database. Retrieved March 4, 2009, from http://www.facs.org/cancer/ncdb/index. html
37. Peng, J.C.; Lee, K.L.; Ingersoll, G.M. An introduction to logistic regression analysis and reporting. J Educ Res 2002, 97(1), 3-14.
38. Stark, A.; Kucera, G.; Lu, M.; Claud, S.; Griggs, J. Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients. Int J Qual Health Care 2004, 16(6), 517-621.
39. Riley, G.F.; Potosky, A.L.; Lubitz, J.D.; Brown, M.L. Stage of cancer at diagnosis for Medicare HMO and fee-for-service enrollees. Am J Public Health 1994, 84(10), 1598-1604.
40. Polite, B.N.; Olopade, O.I. Breast cancer and race. Perspect Biol Med. 2005, 48, S166-S175.
41. Jones, B.A.; Kasl, S.V.; Howe, C.L.; Lachman, M.; Dubrow, R.; Curnen, M.M.C.; Soler-Vila, H.; Beeghly, A.; Duan, F.; Owens, P. African-American/White differences in breast carcinoma. Cancer 2004, 101(6), 1293-1301.
42. Skinner, K.A.; Helsper, J.T.; Deapen, D.; Ye, W.; Sposto, R. Breast cancer: do specialists make a difference? Ann Surg Oncol 2003, 10, 606-615.
43. Bast, Jr., R.C.; Ravdin, P.; Hayes, D.F.; Bates, S.; Fritsche, Jr., H.; Jessup, J.M.; Kemeny, N.; Locker, G.Y.; Mennel, R.G.; Somerfield, M.R. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer. Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19,(6), 1865.
44. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelins in Oncology Breast Cancer. Fort Washington, PA: NCCN, 2009.
45. Goodman, A. Importance of HER-2/Neu positivity as predictor of outcome in DCIS remains controversial. Oncology Times 2007, 29(8)25, 36-38.
46. Siziopikou, K.P.; Khan, S. Correlation of HER2 gene amplification with expression of apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast. Appl Immunohistochem Mol Morphol 2005, 13(1), 14-18.
47. DiGiovanna, M.P.; Chu, P.; Davison, T.L.; Howe, C.L.; Carter, D.; Claus, E.B.; Stern, D.F. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ. Cancer Res 2002, 62(22), 6667-6673.
48. Park, K.; Han, S.; Kim, H.J.; Kim, J.; Shin, E. HER2 status in pure carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006, 48(6), 702-707.